About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Pharmacoeconomics
›
top-articles
Pharmacoeconomics
3.9
(top 10%)
impact factor
3.4K
(top 5%)
papers
106.5K
(top 5%)
citations
124
(top 5%)
h
-index
4.1
(top 10%)
impact factor
3.9K
all documents
112.3K
doc citations
205
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Pharmacoeconomics
1993
2,118
2
The Epidemiology of Obesity: A Big Picture
Pharmacoeconomics
2015
1,843
3
Conducting Discrete Choice Experiments to Inform Healthcare Decision Making
Pharmacoeconomics
2008
1,118
4
Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?
Pharmacoeconomics
2016
819
5
Determining Clinically Important Differences in Health Status Measures
Pharmacoeconomics
1999
767
6
The health economics of bladder cancer
Pharmacoeconomics
2003
725
7
An Introduction to Markov Modelling for Economic Evaluation
Pharmacoeconomics
1998
713
8
Multi-Attribute Health Status Classification Systems
Pharmacoeconomics
1995
702
9
Handling Uncertainty in Cost-Effectiveness Models
Pharmacoeconomics
2000
659
10
The NICE Cost-Effectiveness Threshold
Pharmacoeconomics
2008
643
11
A Comparative Review of Generic Quality-of-Life Instruments
Pharmacoeconomics
2000
627
12
The Burden of Schizophrenia on Caregivers
Pharmacoeconomics
2008
592
13
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Pharmacoeconomics
2015
588
14
Discrete Choice Experiments in Health Economics: A Review of the Literature
Pharmacoeconomics
2014
560
15
Epidemiology and burden of illness of rheumatoid arthritis
Pharmacoeconomics
2004
503
16
Multi-Attribute Preference Functions
Pharmacoeconomics
1995
457
17
Discrete Choice Experiments in Health Economics: Past, Present and Future
Pharmacoeconomics
2019
420
18
The Concept of Clinically Meaningful Difference in Health-Related Quality of Life Research
Pharmacoeconomics
2000
417
19
A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
Pharmacoeconomics
2014
417
20
Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment
Pharmacoeconomics
2006
390
21
Neuropathic Pain
Pharmacoeconomics
2009
373
22
Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis
Pharmacoeconomics
2006
352
23
Cost-Effectiveness Analysis and the Consistency of Decision Making
Pharmacoeconomics
2001
341
24
The Health-Related Quality of Life and Economic Burden of Constipation
Pharmacoeconomics
2005
316
25
German Value Set for the EQ-5D-5L
Pharmacoeconomics
2018
316
26
Healthcare Resource and Lost Labour Costs of Migraine Headache in the US
Pharmacoeconomics
1992
308
27
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
Pharmacoeconomics
2021
302
28
Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
Pharmacoeconomics
2008
299
29
Cost-of-Illness Studies
Pharmacoeconomics
2011
291
30
A Practical Guide for Calculating Indirect Costs of Disease
Pharmacoeconomics
1996
290
31
Standardisation of Costs
Pharmacoeconomics
2002
290
32
Generic Health-Related Quality-of-Life Assessment in Children and Adolescents
Pharmacoeconomics
2006
284
33
Valuation of the Child Health Utility 9D Index
Pharmacoeconomics
2012
280
34
How to Calculate Indirect Costs in Economic Evaluations
Pharmacoeconomics
1998
276
35
A Review of Self-Report Instruments Measuring Health-Related Work Productivity
Pharmacoeconomics
2004
271
36
Cost-of-Illness Studies
Pharmacoeconomics
1992
264
37
Comparative Effectiveness Without Head-to-Head Trials
Pharmacoeconomics
2010
247
38
The Cost and Impact of Health Conditions on Presenteeism to Employers
Pharmacoeconomics
2009
245
39
Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs
Pharmacoeconomics
2007
241
40
A Review of Health-Related Workplace Productivity Loss Instruments
Pharmacoeconomics
2004
233
41
Health Utilities Using the EQ-5D in Studies of Cancer
Pharmacoeconomics
2007
232
42
Returns on Research and Development for 1990s New Drug Introductions
Pharmacoeconomics
2002
230
43
Medicaid Preferred Drug Lists: Cost Containment and Side Effects
Pharmacoeconomics
2006
229
44
Cost-of-Illness Studies
Pharmacoeconomics
2006
226
45
Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample
Pharmacoeconomics
1998
225
46
Costs of Irritable Bowel Syndrome in the UK and US
Pharmacoeconomics
2006
225
47
A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries
Pharmacoeconomics
2004
219
48
Using Value of Information Analysis to Prioritise Health Research
Pharmacoeconomics
2006
218
49
European Healthcare Policies for Controlling Drug Expenditure
Pharmacoeconomics
2003
217
50
Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries
Pharmacoeconomics
2018
215
site/software ©
exaly
; All materials licenced under
CC by-SA
.